We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) reported $11.44 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 20.4%. EPS of $1.18 for the same period compares to $0.10 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $12.03 billion, representing a surprise of -4.92%. The company delivered an EPS surprise of -22.37%, with the consensus EPS estimate being $1.52.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales- Cyramza (Ramucirumab /IMC-1121B) - US: $106.50 million compared to the $97.33 million average estimate based on four analysts. The reported number represents a change of +21% year over year.
Net Sales- International-Humalog [$M]: $210.80 million versus $193.98 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
Net Sales- International-Forteo [$M]: $46.40 million compared to the $38.32 million average estimate based on four analysts. The reported number represents a change of +2.7% year over year.
Net Sales- US-Humulin [$M]: $149.90 million versus the four-analyst average estimate of $141.30 million. The reported number represents a year-over-year change of +3%.
Net Sales- Erbitux [$M]: $152 million versus the four-analyst average estimate of $154.76 million. The reported number represents a year-over-year change of -1.2%.
Net Sales- Forteo [$M]: $118.10 million compared to the $79.25 million average estimate based on four analysts. The reported number represents a change of -19.3% year over year.
Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total: $236 million versus the four-analyst average estimate of $226.52 million. The reported number represents a year-over-year change of +5.3%.
Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total: $250.80 million compared to the $241.15 million average estimate based on four analysts. The reported number represents a change of +8.4% year over year.
Net Sales- Humulin [$M]: $207.10 million versus $197.32 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.2% change.
Net Sales- Neurosciences: $351.80 million versus the four-analyst average estimate of $306.81 million. The reported number represents a year-over-year change of -80.1%.
Net Sales- Oncology [$M]: $2.23 billion versus the four-analyst average estimate of $2.18 billion. The reported number represents a year-over-year change of +27.7%.
Net Sales- Other pharmaceuticals [$M]: $262.80 million versus $192.66 million estimated by four analysts on average.
Shares of Lilly have returned +2.2% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Eli Lilly (LLY - Free Report) reported $11.44 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 20.4%. EPS of $1.18 for the same period compares to $0.10 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $12.03 billion, representing a surprise of -4.92%. The company delivered an EPS surprise of -22.37%, with the consensus EPS estimate being $1.52.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Cyramza (Ramucirumab /IMC-1121B) - US: $106.50 million compared to the $97.33 million average estimate based on four analysts. The reported number represents a change of +21% year over year.
- Net Sales- International-Humalog [$M]: $210.80 million versus $193.98 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
- Net Sales- International-Forteo [$M]: $46.40 million compared to the $38.32 million average estimate based on four analysts. The reported number represents a change of +2.7% year over year.
- Net Sales- US-Humulin [$M]: $149.90 million versus the four-analyst average estimate of $141.30 million. The reported number represents a year-over-year change of +3%.
- Net Sales- Erbitux [$M]: $152 million versus the four-analyst average estimate of $154.76 million. The reported number represents a year-over-year change of -1.2%.
- Net Sales- Forteo [$M]: $118.10 million compared to the $79.25 million average estimate based on four analysts. The reported number represents a change of -19.3% year over year.
- Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total: $236 million versus the four-analyst average estimate of $226.52 million. The reported number represents a year-over-year change of +5.3%.
- Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total: $250.80 million compared to the $241.15 million average estimate based on four analysts. The reported number represents a change of +8.4% year over year.
- Net Sales- Humulin [$M]: $207.10 million versus $197.32 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.2% change.
- Net Sales- Neurosciences: $351.80 million versus the four-analyst average estimate of $306.81 million. The reported number represents a year-over-year change of -80.1%.
- Net Sales- Oncology [$M]: $2.23 billion versus the four-analyst average estimate of $2.18 billion. The reported number represents a year-over-year change of +27.7%.
- Net Sales- Other pharmaceuticals [$M]: $262.80 million versus $192.66 million estimated by four analysts on average.
View all Key Company Metrics for Lilly here>>>Shares of Lilly have returned +2.2% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.